Skip to main content
. Author manuscript; available in PMC: 2020 Sep 3.
Published in final edited form as: Mol Pharm. 2019 Jul 30;16(9):4017–4023. doi: 10.1021/acs.molpharmaceut.9b00671

Table 2.

The absolute amounts and their corresponding local concentrations, doses, and therapeutic NO amounts of the HP-PO polymers tested in the study.

Absolute amount (μg)a Concentration in PBS (mg/mL)b Concentration in the chamber (mg/mL)c Dose (mg/kg)d Therapeutic NO amount (μg/kg)e
30 1 0.3 1.5 47
150 5 1.5 7.5 234
750 25 7.5 37.5 1170
a

The absolute mass of the polymers injected into the chambers;

b

The concentration of polymers in the delivery vehicle (i.e., 30 μL of PBS);

c

The estimated concentration of polymers in the chamber (i.e., 100 μL) after injection;

d

The amount of polymers injected into the chambers normalized to the mass of the mice (20 g);

e

The amount of NO delivered into the chambers, which was estimated by multiplying the NO totals of HP-PO/NO polymers measured in the broth (Table 1) with the tested doses.